Similarly, analysis of combined FIGHT-202 ( n = 104) and FIGHT-207 ( n = 11) data for patients with cholangiocarcinoma (Supplementary Table 6 ) did not result in any change to the identification of co-altered genes significantly correlated with best overall response to pemigatinib, and only TP53 was found to be nominally significant (significance was not maintained following stringency correction for multiple testing).
← all excerpts
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
1
—
—